Acne Awareness Month: Spotlight on Innovation, Impact, and Individualized Care
June is Acne Awareness Month, a timely reminder that acne vulgaris is more than a rite of passage—it’s a complex, chronic skin disease with far-reaching clinical and psychosocial effects. Affecting up to 85% of adolescents and a growing number of adults, acne remains one of the most common reasons for dermatologic consultation worldwide.
The science is advancing fast. From insights into the cutaneous microbiome and inflammatory pathways to the development of novel treatments like clascoterone, topical trifarotene, and light-based modalities, dermatologists today have more options than ever before. Emphasis on antibiotic stewardship, skin-of-color considerations, and long-term disease management is also shifting how we approach care.
This month, the Journal of Drugs in Dermatology (JDD) spotlights acne and rosacea in our June issue, featuring cutting-edge clinical data, expert commentary, and practical pearls for integrating new therapies into daily practice.
We invite you to join the conversation—and elevate your acne care—with JDD’s latest peer-reviewed content.
Looking for additional acne articles. Start here:
Steroids Used to Treat Acne Vulgaris: A Review of Efficacy, Safety, and Clinical Considerations
Never Give Up! Continued Progress in Development of Topical Therapies for Acne Is a Good Thing
